PARKASH S. GILL, M.D.; MARK RARICK, M.D.; RUSSELL K. BRYNES, M.D.; DENNIS CAUSEY, M.D.; CARMEN LOUREIRO, M.D.; ALEXANDRA M. LEVINE, M.D.
Four patients with the acquired immunodeficiency syndrome, and a history of Pneumocystis carinii pneumonia developed severe pancytopenia (hemoglobin, < 85 g/L; granulocytes, ≤ 0.5 x 109/L; platelets, ≤ 30 x 109/L) 12 to 17 weeks after the initiation of azidothymidine (AZT) therapy. The bone marrow was markedly hypocellular in three patients and moderately hypocellular in the fourth. Partial bone marrow recovery was documented within 4 to 5 weeks in three patients, but no marrow recovery has yet occurred in one patient during the more than 6 months since AZT treatment was discontinued. Azidothymidine should be used cautiously, with close monitoring of blood values.
Learn more about subscription options.
Register Now for a free account.
GILL PS, RARICK M, BRYNES RK, CAUSEY D, LOUREIRO C, LEVINE AM. Azidothymidine Associated with Bone Marrow Failure in the Acquired Immunodeficiency Syndrome (AIDS). Ann Intern Med. 1987;107:502–505. doi: 10.7326/0003-4819-107-4-502
Download citation file:
Published: Ann Intern Med. 1987;107(4):502-505.
Hematology/Oncology, Infectious Disease.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only